• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.

Sep 4, 2026 | 2026, Events, Investors

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Deposito del Verbale dell’Assemblea degli Azionisti

May 21, 2026 | 2026, Investors, Press Releases

More details

Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026

May 12, 2026 | 2026, Investors, Press Releases

more details

The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)

May 12, 2026 | 2026, Investors, Press Releases

more detalis

Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026

May 6, 2026 | 2026, Events, Scientific

Dr. Ettore Gilardoni will present a poster entitled “Mass Spectrometry–Based Atlas of the Blood-Accessible Surface Proteome in Syngeneic Brain Tumor Models”. Follow the link for more information

Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

May 6, 2026 | 2026, Events, Scientific

Prof. Philipp Backhaus will give a presentation on “Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET and first experience with [177Lu]Lu-OncoACP3-DOTA in Prostate Cancer Patients”. Follow the link for more details....
« Older Entries

Recent Posts

  • Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.
  • Updated Phase III PIVOTAL Results for Nidlegy™ Published in the Journal of Clinical Oncology
  • Nidlegy™ Marketing Authorization Application Resubmitted to EMA
  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it